钠-葡萄糖共转运蛋白2抑制剂(SGLT2-抑制剂)对糖尿病的机制和治疗研究综述  

Review on the mechanism and treatment of diabetes mellitus with a sodium/glucose cotransporter 2 inhibitor

作　　者：李萌[1] 庞立香 马茜茜 包书茵[1] 付丹妮 白雪[1] LI Meng;PANG Lixiang;MA Qianqian;BAO Shuyin;FU Danni;BAI Xue(School of Public Health,Inner Mongolia Minzu University,Tongliao 028000,China.;Medlical College,Inner Mongolia Minzu University,Tongliao 028000)

机构地区：[1]内蒙古民族大学公共卫生学院,内蒙古通辽028000 [2]内蒙古民族大学医学院,内蒙古通辽028000

出　　处：《中国比较医学杂志》2023年第8期127-132,共6页Chinese Journal of Comparative Medicine

基　　金：国家自然科学基金项目(82004070);内蒙古自治区科技计划项目(2020GG0103)。

摘　　要：糖尿病是全球范围内的一种以糖代谢紊乱为主的慢性病。长期高血糖会导致肾、心脏、血管、神经等多种器官的慢性损害。钠-葡萄糖共转运蛋白2(sodium glucose transporter 2 inhibitors,SGLT2)抑制剂是一种新型的降糖药物,它是以一种不依赖于胰岛素分泌的新的机制来降低血糖水平。此类药物以抑制肾肾小管中负责在尿液重吸收葡萄糖的SGLT-2来降低肾糖阈,排出多余的葡萄糖的方式,使血液循环中的葡萄糖水平下降。此外,SGLT2-抑制剂不仅可以治疗糖尿病,同时还可用于治疗由糖尿病引起的心血管、肾疾病和高血压等疾病。现就钠-葡萄糖共转运蛋白2(SGLT2)抑制剂在糖尿病和并发症中的作用和机理进行综述。Diabetes is a chronic disease with glucose metabolism disorder.Long term hyperglycemia leads to chronic damage of the kidneys,heart,blood vessels,nerves,and other organs.Sodium/glucose cotransporter 2(SGLT2)inhibitors are a new type of hypoglycemic drug that reduces the blood glucose level by a new mechanism independent of insulin secretion.Such drugs reduce the renal glucose threshold by inhibiting SGLT2,which is responsible for reabsorption of glucose in urine in the renal tubules of the kidney,and expelling excess glucose,thereby reducing the glucose level in blood circulation.Additionally,SGLT2 inhibitors not only treat diabetes,but can also be used to treat cardiovascular,renal,hypertension,and other diseases caused by diabetes.This article reviews the role and mechanism of SGLT2 inhibitors in diabetes and its complications.

关 键 词：糖尿病 二型糖尿病 钠-葡萄糖共转运蛋白2抑制剂 作用机制 

分 类 号：R-33[医药卫生]